TrialSignal
Clinical trial intelligence report
Interventional, Randomised, Double-blind, Placebocontrolled, Single- and Multiple-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01975779
Status
COMPLETED
Phase
PHASE1
Sponsor
H. Lundbeck A/S
Executive brief
Investment-Ready Snapshot
This clinical trial, sponsored by H. Lundbeck A/S, evaluated the safety, tolerability, and pharmacokinetics of Lu AE58054 in healthy young Japanese and Caucasian men. The study was designed as a randomized, double-blind, placebo-controlled trial with a total enrollment of 42 participants.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01975779
Indication
Healthy
Modality
small molecule
Target
Lu AE58054
Intervention
Cohort A1: Lu AE58054 or placebo, Cohort A2: Lu AE58054 or placebo, Cohort B1: Lu AE58054
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.